九典制药(300705.SZ)发布上半年业绩，归母净利润2.91亿元，增长2.57%

Core Viewpoint - Jiutian Pharmaceutical (300705.SZ) reported a revenue of 1.512 billion yuan for the first half of 2025, reflecting a year-on-year growth of 10.67% [1] - The net profit attributable to shareholders of the listed company was 291 million yuan, an increase of 2.57% year-on-year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 283 million yuan, showing a year-on-year growth of 10.74% [1] - Basic earnings per share stood at 0.59 yuan [1]